Dr Reddy's slips 11% as US court prevents selling of Opioid treatment drug

The stock slipped 11% to Rs 2,070 on the NSE after the drug maker said the preliminary injunction orders issued on Friday by a US court against the company on the launch of generic Suboxone. Shares of Dr Reddy’s Laboratories have dipped 11% to Rs 2,070 per share on the National Stock Exchange (NSE) in early morning trade after the drug maker said that the preliminary injunction orders issued on Friday by a US court against the company on the launch of generic Suboxone, a sublingual film product indicated for treatment of opioid dependence. On the BSE, the stock slipped 9% to Rs 2,115 in intra-day trade so far.

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php